The clinical and prognostic significance of CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy
- 295 Downloads
Myeloid-derived suppressor cells (MDSCs) are key player in mediating systemic immunosuppression, and their accumulation and expansion in the periphery and tumor have been iteratively observed in patients with various types of cancer. It has been reported that CD14+HLA-DR−/low MDSCs are increased in hepatocellular carcinoma (HCC) patients; however, the clinical significance of MDSC alteration in HCC patients after treatment is poorly studied. In this study, we examined the frequency of MDSCs in 92 HCC patients, 14 chronic liver disease patients without HCC, and 22 healthy controls by flow cytometric analysis. The associations between the clinical features and the frequency of MDSCs were analyzed. In particular, we further examined the prognostic impact of MDSCs on the overall survival of HCC patients receiving radiation therapy. The frequency of MDSCs in HCC patients was significantly increased and correlated with tumor stage, size, burden, and Child-Pugh classification but not with biochemical parameters of liver function. In HCC patients who received radiation therapy, the frequency of MDSCs after treatment significantly decreased and was inversely correlated with overall survival time. In multivariate analysis, only post-treatment MDSC ratio and Child-Pugh classification were correlated with the prognosis of HCC patients. Patients with a high frequency of MDSCs after radiotherapy should be closely followed, and the inhibition of MDSCs may improve the prognosis of patients.
KeywordsMyeloid-derived suppressor cells Hepatocellular carcinoma Radiation therapy Overall survival
We thank Yang Yang for his excellent technical assistance in flow cytometry. This work was supported by the Beijing Natural Science Foundation (No. 7133253). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with ethical standards
The study protocol was approved by the Ethics Committee of Beijing Chao-Yang Hospital. All participants provided written informed consent.
Conflicts of interest
- 5.Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Mizukoshi E, et al. Randomized, phase ii study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011;81:281–90.CrossRefPubMedGoogle Scholar
- 15.Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of garp(+)ctla-4(+)foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73:2435–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Napolitano M, D’Alterio C, Cardone E, Trotta AM, Pecori B, Rega D, et al. Peripheral myeloid-derived suppressor and T regulatory pd-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget. 2015;6:8261–70.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60:1419–30.CrossRefPubMedPubMedCentralGoogle Scholar